A Phase 2 interventional study of AMG 531 and Placebo in Myelodysplastic Syndromes and Thrombocytopenia, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.
Sponsored by Amgen · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one is the 8th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 4th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2006.
This study's enrollment of 39 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 72 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG 531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects with myelodysplastic syndrome (MDS) receiving lenalidomide. Subjects with MDS that are planned to receive at least four cycles of lenalidomide for treatment of their disease are appropriate to screen for this study.
All subjects meeting the eligibility criteria will receive lenalidomide 10 mg capsule by mouth daily every day of each 28-day cycle. Subjects will receive AMG 531 or placebo once a week by subcutaneous injection for 16 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
Biological: AMG 531
Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
Drug: Placebo
Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
Drug: Placebo
500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
Biological: AMG 531
750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
Biological: AMG 531
AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
Subjects in the control group will receive placebo via subcutaneous injection.
Occurrence of a Clinically Significant Thrombocytopenic Event
Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.
Time frame: Treatment period through interim follow-up visit (up to 16 weeks)
Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia
Occurrence of lenalidomide dose reduction and delay due to thrombocytopenia
Time frame: Treatment period (up to 16 weeks)
Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines
CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.
Time frame: Treatment period and post-treatment follow-up (up to 21 weeks)
Platelet Transfusion
Occurrence of one or more platelet transfusions during the treatment period
Time frame: Treatment period (up to 16 weeks)
Participants were enrolled from 14 March 2007 through 24 July 2008
| Milestone | Placebo | Romiplostim (AMG 531) 500 μg | Romiplostim (AMG 531) 750 μg |
|---|---|---|---|
| Started | 12 | 14 | 13 |
| Received study medication | 11 | 13 | 13 |
| Completed | 7 | 8 | 9 |
| Not completed | 5 | 6 | 4 |
| Withdrew: Ineligibility determined | 1 | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 |
| Withdrew: Requirement for alternative therapy | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 3 |
| Milestone | Placebo | Romiplostim (AMG 531) 500 μg | Romiplostim (AMG 531) 750 μg |
|---|---|---|---|
| Started | 7 | 8 | 9 |
| Completed | 1 | 4 | 7 |
| Not completed | 6 | 4 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Requirement for alternative therapy | 2 | 2 | 0 |
| Withdrew: Physician decision | 2 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.
| Participants | Placebo | Romiplostim 500 μg | Romiplostim 750 μg |
|---|---|---|---|
| Occurrence of a Clinically Significant Thrombocytopenic Event | 8 | 4 | 8 |
Occurrence of lenalidomide dose reduction and delay due to thrombocytopenia
| Participants | Placebo | Romiplostim 500 μg | Romiplostim 750 μg |
|---|---|---|---|
| Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia | 6 | 5 | 2 |
CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10\^9/L, neutrophils ≥ 1x10\^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.
| Participants | Placebo | Romiplostim 500 μg | Romiplostim 750 μg |
|---|---|---|---|
| Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines | 1 | 2 | 3 |
Occurrence of one or more platelet transfusions during the treatment period
| Participants | Placebo | Romiplostim 500 μg | Romiplostim 750 μg |
|---|---|---|---|
| Platelet Transfusion | 4 | 4 | 4 |
Collected over Up to 21 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/9 (66.7%) | 8/9 (88.9%) |
| Romiplostim 500 µg | — | 5/14 (35.7%) | 14/14 (100%) |
| Romiplostim 750 µg | — | 4/14 (28.6%) | 14/14 (100%) |
| Event | Placebo | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/9 | 3/14 | 1/14 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 1/14 | 2/14 |
| Back painMusculoskeletal and connective tissue disorders | 0/9 | 2/14 | 0/14 |
| NeutropeniaBlood and lymphatic system disorders | 1/9 | 1/14 | 0/14 |
| Angina pectorisCardiac disorders | 1/9 | 0/14 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 1/14 | 0/14 |
| PyrexiaGeneral disorders | 1/9 | 0/14 | 0/14 |
| BacteraemiaInfections and infestations | 1/9 | 0/14 | 0/14 |
| CellulitisInfections and infestations | 1/9 | 0/14 | 0/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/9 | 0/14 | 0/14 |
| Event | Placebo | Romiplostim 500 µg | Romiplostim 750 µg |
|---|---|---|---|
| FatigueGeneral disorders | 1/9 | 4/14 | 8/14 |
| DiarrhoeaGastrointestinal disorders | 4/9 | 4/14 | 5/14 |
| ConstipationGastrointestinal disorders | 0/9 | 5/14 | 1/14 |
| NauseaGastrointestinal disorders | 0/9 | 3/14 | 5/14 |
| Oedema peripheralGeneral disorders | 3/9 | 5/14 | 3/14 |
| RashSkin and subcutaneous tissue disorders | 2/9 | 5/14 | 5/14 |
| NeutropeniaBlood and lymphatic system disorders | 3/9 | 1/14 | 4/14 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/9 | 4/14 | 2/14 |
| DizzinessNervous system disorders | 3/9 | 2/14 | 1/14 |
| InsomniaPsychiatric disorders | 0/9 | 4/14 | 1/14 |
| Age Continuous(Years) | Placebo | Romiplostim 500 μg | Romiplostim 750 μg | Total |
|---|---|---|---|---|
| Mean | 73.2 ± 15.0 | 72.9 ± 11.4 | 66.7 ± 9.4 | 70.9 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo | Romiplostim 500 μg | Romiplostim 750 μg | Total |
|---|---|---|---|---|
| Female | 4 | 6 | 5 | 15 |
| Male | 8 | 8 | 8 | 24 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romiplostim 500 μg | Romiplostim 750 μg | Total |
|---|---|---|---|---|
| White or Caucasian | 11 | 13 | 12 | 36 |
| Black or African American | 0 | 0 | 1 | 1 |
| Hispanic or Latino | 1 | 1 | 0 | 2 |
| International Prognostic Scoring System (IPSS) Score(Participants) | Placebo | Romiplostim 500 μg | Romiplostim 750 μg | Total |
|---|---|---|---|---|
| 0 | 4 | 4 | 6 | 14 |
| 0.5 | 3 | 6 | 4 | 13 |
| 1.0 | 3 | 2 | 3 | 8 |
| >1.0 | 1 | 1 | 0 | 2 |
| Missing | 1 | 1 | 0 | 2 |
No study locations are listed for this record.
The record gives a start of Dec 2006, a primary completion of Mar 2009 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim